-- Company offers multi-gene panels based on NCCN guidelines to help
clinicians select tests for their individual patients --
SAN FRANCISCO--(BUSINESS WIRE)--
Invitae
Corporation (NYSE:NVTA),
a genetic information company, presented data on its guidelines-based
genetic testing panels at the NCCN
Annual Conference: Advancing the Standard of Cancer Care in
Hollywood, Florida, on Thursday. Invitae offers guidelines-based panel
testing that clinicians can customize to reflect their own diagnoses and
expertise to ensure that clinicians have the right tests for the right
patients.
“We have entered an era where testing for BRCA1 and BRCA2 alone is
inadequate,” said Peter Beitsch, MD, FACS, surgical oncologist, Director
of the Dallas
Breast Center, and past president of the American
Society of Breast Surgeons (ASBS). “Inherited pathogenic mutations
in many other genes lead to breast (and other) cancers and these genes
should also be evaluated in patients who qualify for traditional BRCA1/2
testing. This speaks to the importance of a properly vetted list of
actionable genes tested by a lab with proven quality.”
Invitae presented two studies:
Clinical actionability of panel testing for genes in the 2.2016 NCCN
guidelines for hereditary breast and ovarian cancer (HBOC)
The NCCN guidelines for patient care now describe multi-gene testing for
inherited risks for a number of different cancers. Building off the company’s
study with Massachusetts
General Hospital, Stanford
University, and Beth
Israel Deaconess Medical Center published in JAMA
Oncology in 2015, the authors considered the actionability of
specific genes included in the latest versions of the NCCN guidelines.
Consistent with the publication, most non-BRCA1/2 mutations seen in a
clinically representative population would warrant consideration of a
change in care for both the patient and also any mutation-positive
family members identified through additional testing. Based on Invitae’s
diagnostic practice to date, about 50% more patients would be expected
to have an actionable inherited mutation uncovered by a guidelines-based
panel test, compared to BRCA1/2 testing alone.
Clinical presentations of 111 patients with germline PALB2 mutations:
Looking beyond breast and ovarian cancer
PALB2 is a gene recently added to the NCCN guidelines and which is known
to confer a variable level of lifetime cancer risk, depending on
clinical factors. The study authors examined personal and family cancer
histories for 111 sequential PALB2 carriers identified through Invitae’s
clinical testing practice. A diversity of cancers was observed in these
patients and their family members, including many early-onset cases. A
significant group of patients presented with multiple primary tumors,
including prostate, colorectal, thyroid, endometrial, papillary
urothelial, gastric, melanoma, and urinary tract cancers. These data are
consistent with PALB2 conferring a high and heterogeneous cancer risk in
those patients who are typically referred for genetic testing under
current guidelines.
“The NCCN guidelines recognize that panel testing, compared to the
traditional testing approach, is more cost-effective and can improve
care by including important, additional findings that inform prognosis
and management of patients,” said Robert Nussbaum, MD, chief medical
officer of Invitae. “Invitae provides comprehensive and affordable
high-quality clinical genetic tests in a medically responsible way,
supporting the implementation of clinical guidelines and ensuring our
guidelines-based panels incorporate the most up-to-date NCCN
recommendations.”
Both Invitae abstracts were selected for publication in the May special
issue of Journal
of the National Comprehensive Cancer Network (JNCCN):
Highlights of the Annual Conference.
About Invitae
Invitae Corporation's (NYSE:NVTA) mission is to bring comprehensive
genetic information into mainstream medical practice to improve the
quality of healthcare for billions of people. Invitae’s goal is to
aggregate most of the world’s genetic tests into a single service with
higher quality, faster turnaround time, and lower price than many
single-gene and panel tests today. The company currently provides a
diagnostic service comprising hundreds of genes for a variety of genetic
disorders associated with oncology, cardiology, neurology, pediatrics
and other rare disease areas. For more information, visit our website at ir.invitae.com.
Safe Harbor Statements
This press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995,
including statements relating to the utility of multi-gene panel
testing, including that it is more cost-effective, can improve patient
care, and that more patients would be expected to have an actionable
inherited mutation uncovered by a guidelines-based test, compared to
BRCA1/2 testing alone. Forward-looking statements are subject to risks
and uncertainties that could cause actual results to differ materially,
and reported results should not be considered as an indication of future
performance. These risks and uncertainties include, but are not limited
to: the ability of clinical study results to affect treatment decisions;
the company’s ability to generate substantial demand for its tests; the
company’s ability to develop and commercialize new tests and expand into
new markets; risks associated with the company’s ability to use rapidly
changing genetic data to interpret test results accurately and
consistently; the company’s ability to compete; laws and regulations
applicable to the company’s business, including potential regulation by
the Food and Drug Administration; and the other risks set forth in the
company’s filings with the Securities and Exchange Commission, including
the risks set forth in the company’s Annual Report on Form 10-K for the
fiscal year ended December 31, 2015. These forward-looking statements
speak only as of the date hereof, and Invitae Corporation disclaims any
obligation to update these forward-looking statements.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160401005168/en/
Source: Invitae Corporation